Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2393932 | 0.94 | JAK2 (0.39) | JAK2JAK1 | |
| SCHEMBL2399623 | 0.91 | JAK2 (0.49) | JAK2JAK1 | |
| SCHEMBL20713907 | 0.89 | JAK2 (0.42) | JAK2JAK1 | |
| SCHEMBL29540339 | 0.89 | JAK2 (0.42) | JAK2JAK1 | |
| SCHEMBL20713842 | 0.85 | JAK2 (0.42) | JAK2JAK1 | |
| SCHEMBL2397737 | 0.85 | JAK2 (0.41) | JAK2JAK1 | |
| SCHEMBL2397217 | 0.85 | JAK2 (0.49) | JAK2JAK1 | |
| SCHEMBL871336 | 0.84 | JAK2 (0.43) | JAK2JAK1 | |
| SCHEMBL12263244 | 0.84 | JAK2 (0.42) | JAK2JAK1 | |
| SCHEMBL20713843 | 0.84 | JAK2 (0.38) | JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3409673-B1 | PYRROLOPYRIMIDINE FIVE-MEMBERED AZACYCLIC DERIVATIVE AND APPLICATION THEREOF | HANGZHOU BANGSHUN PHARMACEUTICAL CO LTD (CN) | 2021-06-16 | — | — | EP | disclosed |
| US-10822339-B2 | Pyrrolopyrimidine five-membered azacyclic derivative and application thereof | HANGZHOU HUADONG MEDICINE GROUP BIOPHARMACEUTICAL CO. LTD (CN) | 2020-11-03 | — | — | US | disclosed |
| US-20190040068-A1 | PYRROLOPYRIMIDINE FIVE-MEMBERED AZACYCLIC DERIVATIVE AND APPLICATION THEREOF | Hangzhou Bangshun Pharmaceutical Co., Ltd. (CN) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040068-A1 | PYRROLOPYRIMIDINE FIVE-MEMBERED AZACYCLIC DERIVATIVE AND APPLICATION THEREOF | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885 |
| US-10822339-B2 | Pyrrolopyrimidine five-membered azacyclic derivative and application thereof | JAK2, JAK1, JAK3 | JAK2 1/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.